DiscoverResearch To Practice | Oncology VideosMetastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management (Companion Faculty Lecture)
Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management (Companion Faculty Lecture)

Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management (Companion Faculty Lecture)

Update: 2025-09-22
Share

Description

Featuring a slide presentation and related discussion from Prof Peter Schmid, including the following topics:

  • Evolution of the therapeutic landscape for metastatic triple-negative breast cancer; age of immunotherapy (0:00 )
  • Case: A woman in her early 40s with no actionable mutations (7:29 )
  • Evolution of antibody-drug conjugates (ADCs) in the management of metastatic breast cancer (11:13 )
  • TROP2-directed ADCs (15:22 )
  • Case: A woman in her early 50s with PD-L1-negative, HR-negative, HER2-low de novo metastatic breast cancer (20:21 )
  • Novel strategies utilizing approved and investigational ADCs (23:28 )
  • Case: A woman in her early 60s with loss of HER2 expression on disease progression (31:39 )
  • ADCs in combination with immunotherapy (32:51 )

CME information and select publications

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management (Companion Faculty Lecture)

Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management (Companion Faculty Lecture)

Dr. Neil Love